Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors
NEW ENGLAND JOURNAL OF MEDICINE: ADAGRASIB WITH OR WITHOUT CETUXIMAB IN COLORECTAL CANCERWITH MUTATED KRAS G12C
See Mary Crowley featured in the New England Journal of Medicine.
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
PILOT STUDY OF COMBINATION GEMOGENOVATUCEL-T (VIGIL) AND DURVALUMAB
Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of…
PHASE 1/2 STUDY OF EPACADOSTAT IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH METASTATIC SOLID TUMORS
BETA PRIME: PHASE I STUDY OF ADAPT-001 AS MONOTHERAPY
BETA PRIME, a phase I clinical trial, will study AdAPT-001, an oncolytic adenovirus that carries a TGF-β ‘trap’ +/- a checkpoint inhibitor with the ultimate objective to turn ‘cold’ tumors ‘hot’ and increase response rates.
FIRST-IN-HUMAN PHASE I/IB DOSE-FINDING STUDY OF ADAGRASIB (MRTX849) IN PATIENTS
Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C…